In a phase 3 trial in 176 Japanese adults with moderate to severe palmoplantar pustulosis, apremilast gave PPPASI-50 at week 16 in 68% vs 35% with placebo (difference 32.6%). Diarrhoea (19% vs 3%), soft stools, headache and nausea were more common with apremilast.
RCTn = 176
Terui et al. Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial